AAV-HGFK1 and Ad-p53 cocktail therapy prolongs survival of mice with colon cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2855-2865

  Nie, Biao ^a,b   Shen, Zan ^b   Wen, Jun Bao ^a   Wong, Oscar Gee Wan ^b,c   Hsueh, Wayne D ^b   Huo, Long Fei ^b   Kung, Hsiang Fu ^c   Jiang, Bo ^a   Lin, Marie C M ^b,d  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; SCATTER FACTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IN VITRO STUDY; KRINGLE DOMAIN; MOUSE; NECROSIS; NONHUMAN; NUDE MOUSE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DEPENDOVIRUS; ENDOTHELIAL CELLS; FEMALE; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL ANALYSIS; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049136956     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0366     Document Type: Article

References (37)

1. McLeod HL, McKay JA, Collie-Duguid ES, Cassidy J. Therapeutic opportunities from tumour biology in metastatic colon cancer. Eur J Cancer 2000;36:1706-12.
2. Palmer DH, Chen MJ, Kerr DJ. Gene therapy for colorectal cancer. Br Med Bull 2002;64:201-25.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
5. Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat 1995;36:109-18.
6. Crystal RG. The body as a manufacturer of endostatin. Nat Biotechnol 1999;17:336-7.
7. Dell'Eva R, Pfeffer U, Indraccolo S, Albini A, Noonan D. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy. Endothelium 2002;9:3-10.
8. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000;89:1181-94.
9. Xu R, Sun X, Tse LY, et al. Long-term expression ofangios tatin suppresses metastatic liver cancer in mice. Hepatology 2003;37:1451-60.
10. Lalani AS, Chang B, Lin J, et al. Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther 2004;9:56-66.
11. Otte JM, Schmitz F, Kiehne K, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000;61:237-46.
12. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
13. Chirgadze DY, Hepple JP, Zhou H, et al. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat Struct Biol 1999;6:72-9.
14. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6.
15. Kuba K, Matsumoto K, Date K, et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000;60:6737-43.
16. Nakabayashi M, Morishita R, Nakagami H, et al. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia 2003;46:115-23.
17. Lokker NA, Mark MR, Luis EA, et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992;11:2503-10.
18. Xin L, Xu R, Zhang Q, Li TP, Gan RB. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun 2000;277:186-90.
19. Shen Z, Yang ZF, Gao Y, et al. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res 2008;68:404-14.
20. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007;29:272-84.
21. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1999;1:500-9.
22. Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3:121-30.
23. Spitz FR, Nguyen D, Skibber JM, et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-71.
24. Baek JH, Agarwal ML, Tubbs RR, et al. In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer. J Korean Med Sci 2004;19:834-41.
25. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998;9:2745-60.
26. Yu HK, Kim JS, Lee HJ, et al. Suppression of colorectal cancer liver metastasis and extension of survival by expression ofapolipoprotein( a) kringles. Cancer Res 2004;64:7092-8.
27. Kubota T, Fujiwara H, Amaike H, et al. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci 2004;95:321-7.
28. Fazeli A, Steen RG, Dickinson SL, et al. Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc Natl Acad Sci U S A 1997;94:10199-204.
29. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
30. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001;61:6952-7.
31. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65:3716-25.
32. Gruchala M, Bhardwaj S, Pajusola K, et al. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 2004;6:545-54.
33. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005;5:323-31.
34. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996;70:3227-34.
35. Yakobson B, Koch T, Winocour E. Replication of adeno-associated virus in synchronized cells without the addition ofa helper virus. J Virol 1987;61:972-81.
36. Leppard KN. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. J Gen Virol 1997;78:2131-8.
37. Chen Y, Luk KD, Cheung KM, et al. Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem Biophys Res Commun 2004;317:675-81.